Clinical trials: Therapeutic Agent Toxicity
Volunteers Repeated Drug Poisoning, Alcoholic
Repeated Voluntary Drug Intoxication (IMVr): Characterization of a New Addictive Behavior by Clinical Phenotyping and Functional Imaging
France is one of the European countries with the highest rate of death by suicide, more than 10 400 deaths each year, about 16 people out of 100 000.
- Conditions
- Volunteers Repeated Drug Poisoning, Alcoholic, Volunteers
- Trial name
- Phenot IMVr (NCT02889042)
- Testing
- MRI and biological assessment
- Where
- France
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- University Hospital, Grenoble
Melanoma Stage III, Melanoma Stage IV
Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis
The goal of this clinical trial is to compare the safety and effectiveness of infliximab compared to steroids for the treatment of immune checkpoint inhibitor-induced colitis (ICI colitis) in patients with stage III/IV skin…
- Conditions
- Melanoma Stage III, Melanoma Stage IV, Skin Cancer Stage III, Skin Cancer Stage IV
- Trial name
- NCT04305145
- Testing
- Infliximab, Methylprednisolone, Prednisone
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- Massachusetts General Hospital
Stevens - Johnson Syndrome
G-CSF in the Treatment of Toxic Epidermal Necrolysis
NeupoNET aims to evaluate interest of G-CSF in the treatment of Toxic Epidermal necrolysis. This is a prospective randomized controlled trial.
- Trial name
- NeupoNET (NCT02739295)
- Testing
- recombinant granulocyte - colony stimulating factor, NaCl 0.9%
- Where
- 2 sites in Belgium
- Volunteers
- 10 people
- Sponsor
- University of Liege
Chemotherapeutic Agent Toxicity, Endometrial Adenocarcinoma
Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
This phase I trial is studying the side effects and best dose of cisplatin given together with paclitaxel in treating patients with stage IIB, stage IIC, stage III, or stage IV ovarian epithelial cancer, fallopian tube cancer, or…
- Conditions
- Chemotherapeutic Agent Toxicity, Endometrial Adenocarcinoma, Fallopian Tube Carcinoma, Gastrointestinal Complication
- Trial name
- NCT00814086
- Testing
- Paclitaxel, Cisplatin
- Where
- 7 sites in United States
- Volunteers
- 23 people
- Sponsor
- Gynecologic Oncology Group
Toxic Epidermal Necrolysis
Study of a Potential New Treatment for Patients With Toxic Epidermal Necrolysis (TEN)
To determine whether treatment of patients who have toxic epidermal necrolysis with a drug called remicaide increases the number of patients who are alive 30 days laters.
- Trial name
- NCT00372723
- Testing
- Remicaide (infliximab)
- Sponsor
- Loyola University
Atrial Fibrillation, Medication Adherence
Adherence and Coagulation Assays in Dabigatran-treated Patients With Atrial Fibrillation
In patients with non-valvular atrial fibrillation treated with dabigatran etexilate, the level of adherence will be measured using a questionnaire, the Danish National Prescription Registry and pillcount and will be related to…
- Conditions
- Atrial Fibrillation, Medication Adherence, Blood Coagulation Tests, Anticoagulants; Circulating, Hemorrhagic Disorder
- Trial name
- ARCADE (NCT03280368)
- Testing
- Bloodtest, Questionnaires
- Where
- Denmark
- Volunteers
- 430 people, healthy volunteers welcome
- Sponsor
- Hospitalsenheden Vest
Drug Toxicity, Healthy
Aminotransferase Trends During Prolonged Acetaminophen Dosing
The objective of this study is to monitor liver function tests (blood levels of an indicator of liver function) of healthy people taking the maximum labeled daily dose of acetaminophen compared to people taking placebo for 16 to…
- Trial name
- NCT00743093
- Testing
- acetaminophen
- Where
- 2 sites in United States
- Volunteers
- 398 people, healthy volunteers welcome
- Sponsor
- Denver Health and Hospital Authority
Hepatitis C
Real-world Incidence Proportion of Hepatic Toxicity and All Adverse Drug Reactions (ADRs) in Japanese Patients Receiving Daclatasvir (DCV) Trio Therapy
An observational, postmarketing commitment following the marketing authorization for DCV Trio therapy in Japan
- Trial name
- NCT03071133
- Where
- Japan
- Volunteers
- 344 people
- Sponsor
- Bristol-Myers Squibb
Chemotherapeutic Agent Toxicity, Mucositis
Selenomethionine in Reducing Mucositis in Patients With Locally Advanced Head and Neck Cancer Who Are Receiving Cisplatin and Radiation Therapy
This randomized phase II trial is studying how well selenomethionine (SLM) works in reducing mucositis in patients with locally advanced head and neck cancer who are receiving cisplatin and radiation therapy.
- Conditions
- Chemotherapeutic Agent Toxicity, Mucositis, Radiation Toxicity, Stage III Squamous Cell Carcinoma of the Hypopharynx
- Trial name
- NCT01682031
- Testing
- selenomethionine, cisplatin, radiation therapy
- Where
- 2 sites in United States, New Zealand
- Volunteers
- 18 people
- Sponsor
- Roswell Park Cancer Institute
Kidney Transplant; Complications, Toxicity
Effect of Tacrolimus Formulation on Neurological Side Effects in Older Kidney Transplant Recipients
Previous studies have shown that elderly patients experience higher trough levels of tacrolimus and are more sensitive to the effects of medications, they experience higher occurrence and severity of such medication related…
- Conditions
- Kidney Transplant; Complications, Toxicity, Drug Toxicity, Neurotoxicity
- Trial name
- NCT03461445
- Testing
- Envarsus, IR Tacrolimus
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- University of California, Davis
Antipsychotic Drug- Toxicity
Pattern of Acute Antipsychotic Drug- Toxicity in Children
Pattern of Acute Antipsychotic Drug- Toxicity in Children at Assiut University Children Hospital. Determine the pattern and outcome of acute antipsychotic drug- toxicity of children who are admitted to The emergency department of…
- Trial name
- NCT06125275
- Volunteers
- 50 people
- Sponsor
- Assiut University
Drug/Agent Toxicity by Tissue/Organ, Lung Cancer
Chemotherapy, Amifostine, and Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of chemotherapy.
- Trial name
- NCT00003089
- Testing
- amifostine trihydrate, carboplatin, paclitaxel
- Where
- United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Breast Neoplasms
Attenuating Cancer Treatment-related Toxicity in Oncology Patients With a Tailored Physical Exercise Program
The aim of this study is to determine if therapeutic exercise before anticancer treatment will mitigate the onset or extent of cardiotoxicity comparing to therapeutic exercise performed during anticancer treatment.
- Trial name
- ATOPE (NCT03787966)
- Testing
- ATOPE-B, ATOPE-I
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Universidad de Granada
Non Small Cell Lung Cancer
Bevacizumab Plus Chemotherapy for Advanced Non Small Cell Lung Cancer Patients as 1st Line Treatment
Investigators propose to assess, retrospectively and prospectively the safety and tolerability profile (number of participants with adverse events) of standard chemotherapy and anti-angiogenic agent bevacizumab (Avastin) as first…
- Trial name
- NCT01934465
- Where
- 8 sites in Greece
- Volunteers
- 300 people
- Sponsor
- Hellenic Oncology Research Group
Indicated for Pelvic Radiotherapy, Vaginal Rehabilitation, and Alleviation of Late Toxic Reactions in the Vagina
Vaginal Function Exercisers and Vaginal Dilation Irrigation Drug Administration Tubes Are Used for Vaginal Rehabilitation Therapy in Pelvic Radiotherapy
Gynecological pelvic tumors primarily include ovarian cancer, cervical cancer, and endometrial cancer. Radiotherapy (RT) is one of the key treatment modalities for gynecological tumors.
- Trial name
- Exerciser (NCT07473271)
- Testing
- Vaginal exerciser and vaginal dilator with irrigation tube
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Peking Union Medical College Hospital
Non-small Cell Lung Cancer, Esophageal Cancer
Radiation-induced Toxicity of the Heart
Late side effects in radio(chemo)therapy [R(CH)T] pose a critical limitation to patients' overall survival and quality of life. Even though toxicities of the heart are highly relevant for patients with cancer in the thoracic…
- Conditions
- Non-small Cell Lung Cancer, Esophageal Cancer, Breast Cancer Female
- Trial name
- CorTox (NCT06986291)
- Testing
- Imaging and biomarkers
- Where
- Germany
- Volunteers
- 325 people
- Sponsor
- Technische Universität Dresden
Cancer
Validation of an Electronic Remote Toxicity Management System in Cancer Patients
To assess the psychometric properties (validity, reliability and responsiveness) of the QuestOnco tool, an electronic Remote Toxicity Management System, in adult cancer patients receiving an active anti-cancer treatment.
- Trial name
- eRToMSy (NCT04915274)
- Testing
- uses of an application
- Where
- France
- Volunteers
- 134 people
- Sponsor
- Centre Hospitalier Régional Metz-Thionville
HER2-positive Breast Cancer, Targeted Therapy
Cardiotoxicity of Targeted Therapy for HER-2 Positive Breast Cancer Patients at High Altitude
This is a prospective, multicenter, cohort study aiming to explore the cardiotoxicity of targeted therapy for HER-2 positive breast cancer patients who lives in high altitude area.
- Conditions
- HER2-positive Breast Cancer, Targeted Therapy, Cardiac Toxicity, High Altitude
- Trial name
- NCT05063643
- Testing
- High altitude
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Affiliated Hospital of Qinghai University
Renal Cell Carcinoma
Sunitinib Drug Levels and Outcomes in Kidney Cancer
Sunitinib is an oral drug used for treatment of advanced kidney cancer. The standard dose is 50mg, but many patients require a dose decrease due to side-effects.
- Trial name
- CRESTO (NCT01711268)
- Where
- Australia
- Volunteers
- 35 people
- Sponsor
- Western Sydney Local Health District
Mucositis, Nephrotoxicity
Treatment of Radiation and Cisplatin Induced Toxicities with Tempol
A 10 week trial to assess the ability of Tempol to prevent and/or reduce toxicities associated with cisplatin and radiation treatment in head and neck cancer patients.
- Conditions
- Mucositis, Nephrotoxicity, Ototoxicity
- Trial name
- NCT03480971
- Testing
- Tempol
- Where
- 9 sites in United States
- Volunteers
- 120 people
- Sponsor
- Matrix Biomed, Inc.